Drugs / LY6249492
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07030868 | Jun → Jul 2025 | obesity disorder, type 2 diabetes mellitus | Eli Lilly and Company | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY6249492 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07030868 ↗ |
| Route | Oral | “Administered orally” NCT07030868 ↗ |